Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹312.30up ₹6.10 (1.99%)BSE ₹312.40
Share price at the NSE close on 2 Nov 2026. Previous close ₹306.20.
2 Nov: open ₹306.90, high ₹314.50, low ₹305.90
52-week range of traded prices to 2 Nov 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,152 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.39
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,35,05249.3% delivered
Marksans Pharma results
72 filed, newest first. Page 2 of 2.
May 2014
29 May · Results
Feb 2014
Oct 2013
Jul 2013
May 2013
Feb 2013
Nov 2012
Aug 2012
May 2012
29 May · Results
Apr 2012
27 Apr · Results
Company will publish Annual Audited Results for the entire financial year ended March 31, 2012 before May 30, 2012. Therefore, unaudited financial results for the quarter ended March 31, 2012 will not be published.
Feb 2012
Nov 2011
Aug 2011
Jun 2011
May 2011
28 May · Results
3 May · Results
Company will publish Annual Audited Results for the year ended March 31, 2011 before May 30, 2011. Therefore, unaudited financial results for the quarter ended on March 31, 2011 will not be published.
Feb 2011
Nov 2010
Feb 2010
3 Feb · Results
As per the result of the postal ballot announced on February 02, 2010 the shareholders have approved both the following resolutions, as set out in the notice dated December 29, 2009, with requisite majority: (1) An Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956 relating to sale, lease or otherwise disposal of the API Plants of the Company located at Plot No. A88 & D10, Kurkumbh, MIDC, Pune, and (2) A Special Resolution under Section 81(1A) of the Companies Act, 1956 relating to raising of capital through issue of equity shares and/or equity shares through depository receipts and/or foreign currency convertible bonds and/or any other convertible bonds/securities upto an amount not exceeding USD125 Million.
Apr 2009
21 Apr · Results
Company will publish Annual Audited Results for the year ended March 31, 2009 before June 30, 2009. Therefore, unaudited financial results for the quarter ended on March 31, 2009 will not be published or given to Stock Exchanges.
Feb 2008
29 Feb · Results
Results of the postal ballot declared on February 29, 2008. Further the Company has submitted to the Exchange the copy of the Scrutinizer's report. The copy of the same alongwith the details of Results of postal ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.